Mental stress-induced myocardial ischemia

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)